Connect with us

Technology

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Published

on

CAMBRIDGE, Mass., Aug. 30, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense” or the “Company”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it has received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”). The letter notifies the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company’s ordinary shares listed on the Nasdaq was below USD $1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of USD $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

The Notice has no immediate effect on the Company’s Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the Company’s ordinary shares will continue to trade on the Nasdaq under the symbol “NRSN”.

In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until February 24, 2025, to regain compliance with the minimum bid price. If at any time before February 24, 2025 the bid price of the Company’s ordinary shares closes at or above USD $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement.

In the event the Company does not regain compliance by February 24, 2025, the Company may be eligible for an additional 180 days to regain compliance if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period.

The Company will continue to monitor the closing bid price of its ordinary shares on the Nasdaq between now and February 24, 2025 and seek to cure the deficiency within the prescribed compliance period.  The Company’s business operations are not affected by the notification letter.

If the Company cannot demonstrate compliance by the allotted compliance period(s), Nasdaq’s staff will notify the Company that its ordinary shares are subject to delisting.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. For example, the Company is using forward-looking statements when it discusses regaining compliance with Nasdaq’s continued listing requirements, and timing and effect thereof. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements relating to the consummation of the offering described above, the expected proceeds from the offering, the intended use of proceeds and the timing of the closing of the offering. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include unexpected R&D costs or operating expenses, a delay in the reporting of additional results from PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2024 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-announces-receipt-of-nasdaq-minimum-bid-price-notification-302234276.html

SOURCE NeuroSense

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Towards new trends, gathering new trends and innovating: China Changan makes its debut at the 2025 Shanghai Auto Show

Published

on

By

SHANGHAI, April 24, 2025 /PRNewswire/ — China Changan makes its debut at the 2025 Shanghai Auto Show with the theme of “Towards New Trends, Gathering New Trends, and Innovative Power”, bringing 88 products to showcase its innovative technologies and product portfolio.

Towards new trends, creating core technology driving force

China Changan has built a “1255+” technological innovation system and transformed into an innovative technology group. At the auto show, Chenzhi Technology releases a new generation of intelligent chassis sports integrated solutions, covering EMB full-wire control brake and other technologies, with multiple power combinations, system-level redundancy and other features, and its performance indicators are leading the world. Chongqing Qingshan launches the “GI-Drive2.0” intelligent electric drive platform, which contains 293 invention patents and uses EDS4 distributed electric drive assembly with an efficiency of 96.5%. It demonstrates scenes such as turning around on the spot and shows precise control capabilities.

Gathering new trends and building a smart travel ecosystem

China Changan participates in the exhibition with a “3+2+N” business layout:

Powertrain and electric drive: Dongan Power displays the M15NTDE engine and other products with leading thermal efficiency; Chongqing Qingshan exhibits the all-in-one electric drive assembly; Huachuan Denso brings products such as extended-range generators.

Intelligent chassis: Chenzhi Technology demonstrates its full-stack capabilities including wire-controlled braking and steering; Sichuan Jianan’s third-generation electric drive axle is about to be mass-produced.

Thermal management: The Innovation Research Institute exhibits super-integrated thermal management modules; Southern Inter displays multi-zone air-conditioning boxes and other products.

Electronics, appliances and parts: The Electronics and Appliances Division brings products such as power domain controllers; Hunan Tianyan displays transformation results such as superchargers.

Changan Minsheng Logistics presents full-process digital logistics solutions and intelligent equipment.

Innovation brings together new momentum for the industry

China Changan adheres to the brand connotation of “innovation-led”, provides customized cooperation models, introduces intelligent manufacturing and digital management, and strictly controls quality. At the same time, it promotes green supply chains, deploys battery recycling, explores cutting-edge fields with industry chain partners, and promotes high-quality development of the automobile industry.

 

View original content:https://www.prnewswire.com/apac/news-releases/towards-new-trends-gathering-new-trends-and-innovating-china-changan-makes-its-debut-at-the-2025-shanghai-auto-show-302437149.html

SOURCE China Changan

Continue Reading

Technology

X-PHY Inc Unveils Real-Time Deepfake Detection Tool Ahead of RSA Conference 2025

Published

on

By

Expanding its AI-powered security suite, X-PHY takes aim at the rising threat of AI-generated deception

SAN FRANCISCO, April 24, 2025 /PRNewswire/ — X-PHY Inc, a leading innovator in embedded cybersecurity technology, has announced the launch of its latest solution ahead of RSA Conference (RSAC) 2025 – Deepfake Detector – a real-time deepfake detection tool that empowers users to verify the authenticity of videos, audio, and images directly on their devices, without relying on the cloud. Live demonstrations will be held for the first time during RSAC.

The growth of deepfakes has been exponential – deepfake content on social media alone grew 550% between 2019 and 2023, and the World Economic Forum states it is a key global risk. X-PHY’s innovation is designed to combat AI-generated deception, enabling users to verify the authenticity of digital media – including videos, images, and audio – with up to 90% accuracy, in real-time. This marks X-PHY’s expansion into AI-driven content integrity solutions, bridging data protection with digital trust.

“At X-PHY, we are committed to extending our ethos of Security by Design beyond data protection,” said Camellia Chan, CEO and Co-Founder of X-PHY Inc. “The X-PHY Deepfake Detector strengthens our vision of a Community Root of Trust, where every layer – from hardware to data to content – serves as a checkpoint for authenticity and security. By combining deepfake detection with our existing hardware-embedded defences, we’re ensuring every endpoint not only protects data, but actively discerns and verifies the trustworthiness of the information flowing through it.”

On-Demand Deepfake Detection

Upon activation, the X-PHY Deepfake Detector uses multi-modal AI to analyze video, image, and audio streams in real time. By examining facial micro-expressions, voice fingerprints, and Generative Adversarial Network (GAN)-generated artifacts, it flags signs of manipulation – even across multiple video windows. Detection is performed entirely on-device, preserving privacy and functioning even without an internet connection.

This is achieved through the Deepfake Detector’s use of advanced temporal and spatial AI analysis, powered by pre-trained neural networks. These models are capable of identifying subtle inconsistencies across facial movements, audio waveforms, and image artifacts – common signs of AI-generated content.

When combined with X-PHY’s patented hardware-based protections, this forms a seamless security ecosystem, protecting both stored data and the integrity of digital communications.

Flexible Deployment, Fuss-Free Integration

Designed for seamless adoption, the Deepfake Detector offers flexible deployment options to suit varying enterprise needs. It can be installed as a lightweight software agent on personal computers and laptops running on Windows operating systems or packaged with the X-PHY Cybersecure SSD – creating a unified defense layer that spans data protection, ransomware prevention, and deepfake detection.

The solution is application-agnostic, compatible with leading platforms like Teams, Zoom, Webex, Chrome, YouTube, and Meta. Users can activate it with a single click when joining a meeting, where it runs autonomously for a preset duration and can be re-engaged as needed.

Built on Zero Trust principles, the solution adds an additional layer of authentication and verification at the device level, helping organizations strengthen their cyber resilience against AI-powered deception and reducing reliance on external validation systems that often introduce unnecessary operational complexity.

X-PHY Deepfake Detector is now available for purchase through the official X-PHY website and from authorized global channel partners. For enterprise enquiries or bulk deployments, please contact our sales team at info@x-phy.com

Experience live demonstrations at X-PHY Inc’s Booth #5368, located in the North Expo Hall of the Moscone Center, from April 28 to May 1 during RSA Conference 2025.

About X-PHY Inc

X-PHY Inc is a pioneering cybersecurity company dedicated to hardware-based cybersecurity solutions that protect data at its core. Built on the principle of Security by Design, X-PHY embeds protection directly at the physical layer for proactive, autonomous, and real-time defense against evolving cyber threats. Headquartered in California, USA, X-PHY Inc was established in 2021 and has since developed a growing portfolio of 43 patents, reinforcing its commitment to innovative AI-embedded security at the hardware level. The company’s patented solutions safeguard endpoints, servers, and data centers, ensuring zero-trust resilience across industries.

X-PHY Inc is part of the Flexxon Group, a leader in hardware engineering and memory solutions, leveraging its legacy of innovation and expertise in secure storage to build cutting-edge cybersecurity technologies for the digital world.

For more information, please visit:
X-PHY: x-phy.com
Flexxon: flexxon.com 

View original content:https://www.prnewswire.com/news-releases/x-phy-inc-unveils-real-time-deepfake-detection-tool-ahead-of-rsa-conference-2025-302435625.html

SOURCE X-PHY Inc

Continue Reading

Technology

Bright Scholar Schedules Unaudited Financial Results for the Second Quarter of Fiscal 2025 Ended February 28, 2025

Published

on

By

CAMBRIDGE, England and FOSHAN, China, April 24, 2025 /PRNewswire/ — Bright Scholar Education Holdings Limited (“Bright Scholar,” the “Company,” “we” or “our”) (NYSE: BEDU), a global premier education service company, today announced that it will release its unaudited financial results for the second quarter of fiscal 2025 ended February 28, 2025, on April 28, 2025, before the US market opens.

The Company’s management will host an earnings conference call at 7:00 a.m. U.S. Eastern Time (7:00 p.m. Beijing/Hong Kong Time) on April 28, 2025.

Dial-in details for the earnings conference call are as follows:

Mainland China:

4001-201203

Hong Kong:

800-905945

United States:

1-888-346-8982

International:

1-412-902-4272

Participants should dial-in at least 5 minutes before the scheduled start time and ask to be connected to the call for “Bright Scholar Education Holdings Limited.”

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://ir.brightscholar.com/.

A replay of the conference call will be accessible after the conclusion of the live call until May 5, 2025, by dialing the following telephone numbers:

United States Toll Free:

1-877-344-7529

International:

1-412-317-0088

Replay Passcode:

2410484

About Bright Scholar Education Holdings Limited

Bright Scholar is a global premier education service Group. The Company primarily provides quality international education to global students and equips them with the critical academic foundation and skillsets necessary to succeed in the pursuit of higher education.  

For more information, please visit: https://ir.brightscholar.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s business plans and development, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

IR Contact:
Email: BEDU@thepiacentegroup.com
Phone: +86 (10) 6508-0677/ +1-212-481-2050

Media Contact:
Email: media@brightscholar.com

 

View original content:https://www.prnewswire.com/news-releases/bright-scholar-schedules-unaudited-financial-results-for-the-second-quarter-of-fiscal-2025-ended-february-28-2025-302437087.html

SOURCE Bright Scholar Education Holdings Ltd.

Continue Reading

Trending